2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 987

Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE
Abstract Number: 1837

Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
Abstract Number: 402

Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 1433

Predicting Response to Osteoarthritis Treatment Based on Patient Reported Outcome Measures and Quantitative Sensory Testing
Abstract Number: 593

Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Abstract Number: 644

Predicting the Risk for Lymphoma Development in Sjögren’s Syndrome: An Easy to Use Clinical Tool
Abstract Number: 2584

Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Abstract Number: 1318

Prediction of Large Joint Destruction in Patients with Rheumatoid Arthritis Using FDG-PET/CT: A Prospective Study
Abstract Number: 3196

Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Abstract Number: 575

Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
Abstract Number: 3040

Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome
Abstract Number: 1674

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis
Abstract Number: 1207

Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Abstract Number: 1062

Predictive Validity of the ASAS-Classification Criteria for Axial and Peripheral Spondyloarthritis – a Final Analysis
Abstract Number: 2620

Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].